Metraipolis › archive › dc_4ab91fe517bc

Protocol to define the in situ proteome of endogenous PRC2 bodies in the triple-negative breast cancer cell line BoM-1833 using optoproteomics — Europe PMC PMID:42133489

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42133489
DOI
10.1016/j.xpro.2026.104578
License (as archived)
solo-consultazione
Archived
2026-11-02T09:37:45.178Z
SHA-256 of the archived text
60f80c314fdd9c695d47a7bb98bfc1a550cbdba77a54846290fdb47a1baefc65
Stable URL of this page
https://metraipolis.com/documento/dc_4ab91fe517bc

How to cite

Protocol to define the in situ proteome of endogenous PRC2 bodies in the triple-negative breast cancer cell line BoM-1833 using optoproteomics — Europe PMC PMID:42133489 — Europe PMC (en), https://europepmc.org/article/MED/42133489 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4ab91fe517bc (Metraipolis archive dc_4ab91fe517bc, sha256 60f80c314fdd9c695d47a7bb98bfc1a550cbdba77a54846290fdb47a1baefc65)
BibTeX
@misc{dc4ab91fe517bc,
  title = {Protocol to define the in situ proteome of endogenous PRC2 bodies in the triple-negative breast cancer cell line BoM-1833 using optoproteomics — Europe PMC PMID:42133489},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42133489},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4ab91fe517bc; sha256 60f80c314fdd9c695d47a7bb98bfc1a550cbdba77a54846290fdb47a1baefc65},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42133489. Agents can read the archived copy with the MCP tool read_document.